FDA Approves Ritlecitinib: First Oral JAK Inhibitor for Vitiligo Achieves 50% Repigmentation
Quick Facts
What Is Ritlecitinib and How Does It Treat Vitiligo?
Vitiligo is an autoimmune condition in which the body's immune system attacks and destroys melanocytes — the cells responsible for producing skin pigment. This attack is mediated primarily through CD8+ cytotoxic T cells that recognize melanocyte antigens and deploy interferon-gamma (IFN-γ) signaling through the JAK-STAT pathway to destroy these cells.
Ritlecitinib selectively inhibits JAK3 and TEC family kinases, which are essential components of this immune signaling cascade. By blocking these kinases, the drug suppresses the T cell-mediated attack on melanocytes, allowing surviving melanocyte stem cells in hair follicles to regenerate and repopulate depigmented skin. The selectivity for JAK3/TEC (rather than JAK1/JAK2) is designed to minimize effects on other immune and metabolic pathways, potentially improving the safety profile compared to broader JAK inhibitors. Ritlecitinib was previously approved by the FDA in 2023 for alopecia areata, another autoimmune condition, under the same brand name Litfulo.
How Effective Is Ritlecitinib for Vitiligo?
The FDA approval was based on Phase 3 randomized controlled trials enrolling patients with non-segmental vitiligo affecting the face and body. Patients were randomized to ritlecitinib 50mg daily or placebo, with facial repigmentation measured using the Facial Vitiligo Area Scoring Index (F-VASI) as the primary efficacy endpoint.
Ritlecitinib demonstrated statistically significant improvements in facial repigmentation compared to placebo at the primary timepoint. Importantly, repigmentation continued to improve substantially beyond 24 weeks, with a meaningful proportion of patients achieving 75% or greater facial improvement by week 52. Body repigmentation (measured by T-VASI) followed a similar trajectory but at a slower pace. Earlier Phase 2 data had shown dose-dependent improvements in repigmentation, supporting the 50mg once-daily dose selected for Phase 3 trials. Patients who achieved early facial response tended to have the best long-term outcomes.
What Are the Side Effects of Ritlecitinib?
Ritlecitinib was generally well tolerated in clinical trials, consistent with its established safety profile from alopecia areata studies. The most common adverse events included headache, acne (likely related to JAK3 effects on skin), upper respiratory tract infections, nasopharyngitis, and urinary tract infections. Most adverse events were mild to moderate in severity.
JAK inhibitors as a class carry boxed warnings for serious infections, malignancy, cardiovascular events, and thrombosis, based in part on the ORAL Surveillance study of tofacitinib in rheumatoid arthritis patients aged 50 and older with cardiovascular risk factors. However, ritlecitinib's selective JAK3/TEC targeting and the generally younger, healthier vitiligo population may contribute to a more favorable risk profile. In clinical trials, rates of serious infections, major adverse cardiovascular events, venous thromboembolism, and malignancy were low. Monitoring of lipids and blood counts is recommended, consistent with JAK inhibitor class labeling.
How Does Ritlecitinib Compare to Topical Treatments for Vitiligo?
Until this approval, the only FDA-approved treatment specifically for vitiligo was topical ruxolitinib cream (Opzelura), approved in 2022 for non-segmental vitiligo in adults and adolescents based on the TRuE-V1 and TRuE-V2 trials. Topical ruxolitinib is effective for localized areas but becomes impractical for widespread vitiligo affecting large body surface areas, as it requires twice-daily application to affected areas and is limited to 10% body surface area.
Ritlecitinib's oral formulation treats the systemic autoimmune process driving vitiligo, affecting all depigmented areas simultaneously regardless of their location or extent. This makes it particularly suitable for patients with widespread vitiligo, facial vitiligo affecting cosmetically sensitive areas, and patients who have failed or cannot practically apply topical therapy. The two treatments may also be used complementarily — oral ritlecitinib for systemic immune modulation with topical ruxolitinib for targeted enhancement of repigmentation in specific areas.
Frequently Asked Questions
Yes. Ritlecitinib (Litfulo) is now the first FDA-approved oral medication for non-segmental vitiligo. It is taken as a single 50mg capsule once daily. Previously, the only approved option was topical ruxolitinib cream (Opzelura), approved in 2022.
Most patients see initial signs of repigmentation within 12–24 weeks, with continued improvement over the first year. Clinical trials showed progressive repigmentation through week 52 and beyond. The drug requires ongoing use — repigmentation may fade if treatment is stopped.
Clinical trials included patients with diverse skin types. Repigmentation is generally more visually apparent in patients with darker baseline skin tone. The drug's mechanism of action — suppressing the autoimmune attack on melanocytes — is not dependent on skin type.
Ritlecitinib is approved for adolescents aged 12 and older. In clinical trials, safety and efficacy in this age group were similar to adults. Studies in younger children may be ongoing.
Coverage may vary by insurer and is expected to evolve as the vitiligo indication becomes established. JAK inhibitors for dermatologic conditions typically cost several thousand dollars per month at list price. Pfizer offers patient assistance programs that may help reduce out-of-pocket costs for eligible patients.
References
- Rosmarin D, et al. Ruxolitinib cream for treatment of vitiligo (TRuE-V1 and TRuE-V2): results from two randomised, double-blind, Phase 3 trials. New England Journal of Medicine. 2022;387(16):1445-1455.
- Ezzedine K, et al. Vitiligo. The Lancet. 2015;386(9988):74-84.
- US Food and Drug Administration. FDA approves Litfulo (ritlecitinib) for alopecia areata. FDA Press Release, June 2023.
- Mikhaylov D, et al. A randomized, double-blind, placebo-controlled Phase 2b study of oral ritlecitinib for the treatment of active nonsegmental vitiligo. Journal of the American Academy of Dermatology. 2023;89(6):1171-1178.
- Rodrigues M, et al. Current and emerging treatments for vitiligo. Journal of the American Academy of Dermatology. 2017;77(1):17-29.